VLS Valneva SE

VALNEVA Declaration of shares and voting rights - November 30, 2023

VALNEVA Declaration of shares and voting rights - November 30, 2023

VALNEVA

Declaration of shares and voting rights

November 30, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: December 6, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 138,912,142



ordinary shares with a par value of €0.15 each
162,178,538Double voting rights granted on 569 ordinary shares



 
Between November 4 & November 26, 2023



 
162,054,216

  

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Olfa Taamallah ... (+3)
  • Olfa Taamallah
  • Roy Külter
  • Yan Derocles
Martial Descoutures
  • Martial Descoutures
Olfa Taamallah ... (+3)
  • Olfa Taamallah
  • Roy Külter
  • Yan Derocles
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreeme...

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus Saint-Herblain, France, June 26, 2025 – , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® and ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch